Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
E: investor-relations@haleon.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,969.90 | 10.20 | 0.13% |
| CAC 40 | 7,335.40 | 62.28 | 0.86% |
| DAX 40 | 21,253.70 | 298.87 | 1.43% |
| Dow JONES (US) | 40,396.28 | 128.51 | -0.32% |
| FTSE 100 | 8,249.12 | 114.78 | 1.41% |
| HKSE | 21,466.27 | 48.87 | 0.23% |
| NASDAQ | 16,775.47 | 56.01 | -0.33% |
| Nikkei 225 | 34,267.54 | 285.18 | 0.84% |
| NZX 50 Index | 12,011.34 | 96.20 | -0.79% |
| S&P 500 | 5,391.79 | 14.18 | -0.26% |
| S&P/ASX 200 | 7,761.70 | 13.10 | 0.17% |
| SSE Composite Index | 3,267.66 | 4.85 | 0.15% |